Bulletin du Cancer Journal Citation Rate 2026

ISSN 0007-4551 eISSN 1769-6917 Elsevier BV FR

Q3 Quartile

About Bulletin du Cancer
{# Self-contained "answer block": one dense, LLM-quotable paragraph stating every core fact with an explicit as-of year, server-rendered and unique per journal. This is the canonical fact statement — other sections add narrative, they do not restate these numbers. #}

Bulletin du Cancer (BDC) is a peer-reviewed academic journal covering Cancer Immunotherapy and Biomarkers and Cancer Treatment and Pharmacology, published by Elsevier BV in FR, catalogued under ISSN 0007-4551 (e-ISSN 1769-6917). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 0.34 (Q3 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model (APC ~$1790 USD).

Bulletin du Cancer Citation Rate 2026 — In Context

Bulletin du Cancer has a 2025 2-Year Citation Rate (OpenAlex) of 0.34, placing it in the Q3 quartile within the Cancer Immunotherapy and Biomarkers research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.

Bulletin du Cancer operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view.

Researchers looking to publish in Bulletin du Cancer should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Bulletin du Cancer against similar journals in the field, use our journal comparison tool.

Submission Tips for Bulletin du Cancer
  • Budget $1790 for the Article Processing Charge. Check if your institution or funder covers OA fees.
  • This journal covers Cancer Immunotherapy and Biomarkers, Cancer Treatment and Pharmacology, Colorectal Cancer Treatments and Studies. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Bulletin du Cancer Compares
Citation Rate vs Field Avg
-77%
Field avg: 1.46
APC vs Field Avg
-37%
Field avg: $2832

Compared against 8 journals in the same research areas.

ISSN (Print) 0007-4551
ISSN (Online) 1769-6917
Publisher Elsevier BV
Country France
APC / Cost $1790 USD
In-depth profile & metrics

Bulletin du Cancer is published by Elsevier BV and based in France. It runs on a subscription or hybrid model with an article-processing charge of USD 1790.

In our subject taxonomy, Bulletin du Cancer is classified under Cancer Immunotherapy and Biomarkers, Cancer Treatment and Pharmacology, Colorectal Cancer Treatments and Studies and Health, Medicine and Society.

Bulletin du Cancer is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.

Its most recent citation rate stands at 0.336.

Research Areas
Links
Frequently Asked Questions about Bulletin du Cancer

Bulletin du Cancer does not hold a Clarivate (JCR) Impact Factor on JournalsHub. Its 2-year citation rate, computed from OpenAlex open citation data, is 0.336 — an open proxy for citation impact, not the licensed JCR Impact Factor.

No, Bulletin du Cancer is not an open access journal.

The Article Processing Charge (APC) for Bulletin du Cancer is $1790 USD.

Bulletin du Cancer is published by Elsevier BV.

Bulletin du Cancer shows strong legitimacy signals: it is indexed in OpenAlex. Indexing in recognised databases such as Scopus and DOAJ is a reliable indicator of a peer-reviewed, non-predatory journal, because predatory titles are typically excluded from them. Always confirm the journal's scope and editorial board fit your work before submitting.

The ISSN of Bulletin du Cancer is 0007-4551. Its electronic ISSN (eISSN) is 1769-6917.

Bulletin du Cancer sits in the Q3 quartile based on its latest impact factor of 0.34, ranked across all journals in our database.
Live Indexing Status
Updated April 2026

Track real-time indexing metrics to ensure this journal meets your academic requirements.

OpenAlex
Verified
DOAJ
Non-OA
Predatory Check
Clean
Citation Rate
0.336
2-Year Citation Rate (OpenAlex) · 2025
Historical Trend
Initial data points only
Citation Rate by Year
Year Value Source
2025 0.336 2-Year Mean Citedness (OpenAlex)

Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.

Related Journals in Your Field

Metadata

Last updated: Apr 24, 2026

Updated by: openalex_bulk

OpenAlex ID: S22998730

Get weekly updates for Cancer Immunotherapy and Biomarkers journals

Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.

Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now
Compare 0 Open → Clear
Save your viewing history
You've browsed several journals this session. Sign in to track them in one place and get weekly impact-factor updates.
Save with Google